Section Arrow
NTRA.NASDAQ
- Natera
Quotes are at least 15-min delayed:2026/02/25 07:07 EST
Pre Market
Last
 212.74
+3.21 (+1.53%)
Bid
197.46
Ask
220.5
High 213 
Low 209 
Volume 132 
Regular Hours (Closed)
Last
 209.53
+0.18 (+0.09%)
Day High 
212.48 
Prev. Close
209.35 
1-M High
246.265 
Volume 
693.45K 
Bid
197.46
Ask
220.5
Day Low
207.22 
Open
208.4 
1-M Low
194.02 
Market Cap 
29.19B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 211.34 
20-SMA 217.91 
50-SMA 228.25 
52-W High 256.36 
52-W Low 125.38 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.29/0.96
Enterprise Value
29.29B
Balance Sheet
Book Value Per Share
8.98
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
1.70B
Operating Revenue Per Share
6.68
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
XWELXWELL0.378+0.037+10.85%-- 
Pre Market 0.8267 +0.4487 +118.70%
MYGNMyriad Genetics4.43+0.03+0.68%-- 
Pre Market 4.44 +0.01 +0.23%
GRALGRAIL Inc.50.35+7.32+17.01%-- 
Pre Market 50.17 -0.18 -0.36%
DHRDanaher Corp209.19-1.73-0.82%43.4PE
Pre Market 208.55 -0.64 -0.31%
AAgilent Technologies124.4+0.2+0.16%27.18PE
Pre Market 124.65 +0.25 +0.20%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.